Business
Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company
VILLEJUIF, France, May 18, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), announces that it has entered into a binding term-sheet with a biotech company currently operating in stealth mode, setting out the principal terms of a collaboration and exclusive worldwide license. The final terms remains subject to the signing of
About this update from Valerio Therapeutics
[{"type":"text","content":"Binding term-sheet for a potential aggregate amount of up to USD 200 million and tiered royalties","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"VILLEJUIF, France, May 18, 2026--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), announces that it has entered into a binding term-sheet with a biotech company currently operating in stealth mode, setting out the principal terms of a collaboration and exclusive worldwide license. The final terms remains subject to the signing of the full Collaboration and License Agreement.","length":506,"tagName":"p"},{"type":"text","content":"Under the terms of the binding term-sheet, Valerio will apply its proprietary V-Body platform, combining single-domain antibody discovery, chemistry and oligonucleotide conjugation capabilities, to discover and generate novel targeted therapeutic compounds against selected collaboration targets. Valerio will lead and be responsible for the research and discovery phase, while its partner will assume full responsibility for subsequent worldwide development, manufacturing and commercialization.","length":496,"tagName":"p"},{"type":"text","content":"Under the terms of the binding term-sheet, Valerio would be eligible to receive aggregate potential milestone payments up to USD 200 million, as well as tiered royalties, subject to the execution of a definitive agreement and the achievement of specified events and other terms.","length":278,"tagName":"p"},{"type":"text","content":""This contemplated collaboration represents an important validation of Valerio’s integrated platform and of the quality of the science and know-how developed by our team. Partnering with a company of this caliber reinforces our conviction that Valerio’s V-Body technology can address highly relevant therapeutic opportunities and generate value through focused, non-dilutive partnerships," said Julien Miara, Chief Executive Officer of the Company.","length":458,"tagName":"p"},{"type":"text","content":"Although the partner’s identity remains confidential, Valerio believes that the quality of its shareholder base and its fo...